These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 9239805)

  • 21. Pharmaceutical study of suppository formulations for improved in vivo kinetics of rifampicin.
    Taki H; Ogawa K; Nikai T
    Kekkaku; 2008 Jun; 83(6):451-6. PubMed ID: 18634449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of oral charcoal and urine pH on dextropropoxyphene pharmacokinetics.
    Kärkkäinen S; Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23(4):219-25. PubMed ID: 2987139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms.
    Agrawal S; Panchagnula R
    Biopharm Drug Dispos; 2005 Nov; 26(8):321-34. PubMed ID: 16059874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats.
    Ma L; Wei Y; Zhou Y; Ma X; Wu X
    Arch Pharm Res; 2011 Nov; 34(11):1939-43. PubMed ID: 22139693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biowaiver monographs for immediate release solid oral dosage forms: rifampicin.
    Becker C; Dressman JB; Junginger HE; Kopp S; Midha KK; Shah VP; Stavchansky S; Barends DM
    J Pharm Sci; 2009 Jul; 98(7):2252-67. PubMed ID: 19160441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of amitriptyline influenced by oral charcoal and urine pH.
    Kärkkäinen S; Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):326-32. PubMed ID: 3015809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Competitive decrease of rifampicin absorption by a dominant absorption of p-aminosalicylic acid under the simultaneous administration of both drugs].
    Nakagawa H
    Kekkaku; 1988 Oct; 63(10):629-43. PubMed ID: 3204877
    [No Abstract]   [Full Text] [Related]  

  • 28. Gastrointestinal dialysis of disopyramide in healthy subjects.
    Arimori K; Kawano H; Nakano M
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):280-4. PubMed ID: 2737797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of activated charcoal on isoniazid absorption in rabbits.
    Ofoefule SI; Onuoha LC; Okonta MJ; Udeogaranya PO; Orisakwe OE
    Boll Chim Farm; 2001; 140(3):183-6. PubMed ID: 11486611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seromucosal transport of intravenously administered carbamazepine is not enhanced by oral doses of activated charcoal in rats.
    Eyer F; Jung N; Neuberger H; Witte A; Poethko T; Henke J; Zilker T
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):337-46. PubMed ID: 18248517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers.
    Pargal A; Rani S
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):70-9. PubMed ID: 11263520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption.
    Ellard GA; Fourie PB
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S301-8; discussion S317-21. PubMed ID: 10593709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of delayed administration of activated charcoal on the absorption of conventional and slow-release verapamil.
    Laine K; Kivistö KT; Neuvonen PJ
    J Toxicol Clin Toxicol; 1997; 35(3):263-8. PubMed ID: 9140320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
    Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.
    Droste JA; Verweij-van Wissen CP; Kearney BP; Buffels R; Vanhorssen PJ; Hekster YA; Burger DM
    Antimicrob Agents Chemother; 2005 Feb; 49(2):680-4. PubMed ID: 15673751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronopharmacokinetics of rifampicin.
    Avachat MK; Rambhau D; Rao VV; Rao BR; Rao JV
    Indian J Physiol Pharmacol; 1992 Oct; 36(4):251-4. PubMed ID: 1291477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G; Fourie PB; Padayatchi N; Onyebujoh PC; McIlleron H; Smith PJ; Gabriels G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma and saliva concentrations of rifampicin in man after oral administration.
    Orisakwe OE; Ofoefule SI
    Tokai J Exp Clin Med; 1996 Feb; 21(1):45-9. PubMed ID: 9239804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of ipecac and activated charcoal/cathartic. Prevention of salicylate absorption in a simulated overdose.
    Curtis RA; Barone J; Giacona N
    Arch Intern Med; 1984 Jan; 144(1):48-52. PubMed ID: 6140906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.